Stocksigma LogoStocksigma Logo

Emcure Pharmaceuticals Outlines Strong FY26 Growth and Multi-Vector Strategic Expansion

Emcure Pharmaceuticals reported FY26 revenue of INR 92,035 Mn (+16.6% YoY) and PAT of INR 9,413 Mn (+33.1% YoY), driven by EBITDA margin expansion to 19.4%

Emcure Pharmaceuticals Outlines Strong FY26 Growth and Multi-Vector Strategic Expansion

Emcure Pharmaceuticals Ltd 路 Investor Presentation 路 25 Sept 2026, 10:06 pm

Emcure Pharmaceuticals Outlines Strong FY26 Growth and Multi-Vector Strategic Expansion Emcure Pharmaceuticals reported FY26 revenue of INR 92,035 Mn (+16.6% YoY) and PAT of INR 9,413 Mn (+33.1% YoY), driven by EBITDA margin expansion to 19.4% and RoCE reaching 23.7%. International revenue rose 22.2% YoY to INR 51,766 Mn, while domestic formulations grew 10.0% YoY to INR 40,270 Mn with chronic mix crossing 60%. In Q1 FY27, revenue climbed 22.8% YoY to INR 25,804 Mn and PAT surged 36.2% YoY to INR 2,925 Mn. Emcure targets FY26鈥揊Y30 growth via complex injectables, biologics, and in-licensing deals.

Original exchange filing (PDF)

More announcements from Emcure Pharmaceuticals Ltd

All Emcure Pharmaceuticals Ltd announcements